The News That Sparked This Post Tempus AI’s acquisition of OneOme’s pharmacogenomics (PGx) assets is making headlines in precision medicine circles. Most observers see this as an oncology play. They’re not wrong—Tempus has built its reputation on molecular oncology and AI-driven insights. But here’s
Hows & Whys
Why listen to me? Because I’m not here to sell platitudes. I’m here to share the soapboxes I stand on every day, bust the myths that make care worse, and offer the kind of practical wisdom you only get when you’ve sat at the bedside for thousands of hours.
Hows & Whys
If you want evidence-driven insights, humor, and the occasional rant that makes you rethink how we care for people when it matters most, welcome aboard.
This is Rounds and Rants, a brand new site by Kyle Edmonds that's just getting started. Things will be up and running here shortly, but you can subscribe in the meantime if you'd like to stay up to date and receive emails when new content is